Polymerase Capital

Polymerase Capital operates as a venture capital firm specializing in seed and early-stage investments within the life sciences sector. The firm identifies and supports nascent companies developing novel biological and medical innovations. Their approach centers on providing capital and strategic guidance to advance therapeutics, diagnostics, and other biotechnology ventures from their foundational stages to address critical scientific and healthcare challenges.

Founded in 2021, Polymerase Capital was established by Thomas W. Chalberg, PhD. Chalberg leveraged his deep operational and scientific experience, including his background as a founder and managing director of iRenix Medical. His insight likely stemmed from recognizing a need for dedicated early-stage capital and informed mentorship to accelerate promising life science breakthroughs through their complex development cycles.

The firm’s clientele comprises early-stage life science companies seeking initial funding and strategic partnership to translate scientific discoveries into viable commercial entities. Polymerase Capital aims to foster the growth of transformative technologies that address significant unmet medical needs. Its long-term vision is to accelerate the development of groundbreaking solutions, ultimately contributing to advancements in human health and well-being across diverse therapeutic areas.